In early January of 2024, Qvin made history; the FDA clearance of its Q-Pad and A1c Test marked the first FDA approval for menstrual blood health testing.
We invested in Arsenale! Arsenale is building an end-to-end, vertically integrated, AI-driven biomanufacturing platform.
We invested in Focalx! Focalx is building an AI-powered, end-to-end platform for vehicle inspections, making manual inspection errors a thing of the past.
Our portfolio company, Garden, is joining forces with Incredibuild to enhance software delivery for development teams. Together, they plan to enable faster code-to-deployment across applications in the future.